Adenosine 5'-triphosphate (ATP) supplements are not orally bioavailable: a randomized, placebo-controlled cross-over trial in healthy humans

Journal of the International Society of Sports Nutrition

Volumn 9, Issue , 2012, Pages

  Arts, Ilja C W ^a   Coolen, Erik J C M ^a   Bours, Martijn J L ^a   Huyghebaert, Nathalie ^b   Stuart, Martien A C ^c   Bast, Aalt ^a   Dagnelie, Pieter C ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b GHENT UNIVERSITY   (Belgium)

^c WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

ATP; Bioavailability; Gastrointestinal transit; Metabolism; Multi particulate supplement; Nutritional supplement

Indexed keywords

NASO;

EID: 84862175665     PISSN: None     EISSN: 15502783     Source Type: Journal    
DOI: 10.1186/1550-2783-9-16     Document Type: Article

References (46)

1. Burnstock G. Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol Rev 2006, 58:58-86. 10.1124/pr.58.1.5, 16507883.
2. Bours MJ, Swennen EL, Di Virgilio F, Cronstein BN, Dagnelie PC. Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 2006, 112:358-404. 10.1016/j.pharmthera.2005.04.013, 16784779.
3. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004, 350:1093-1103. 10.1056/NEJMoa035700, 15014182.
4. Duchen K, Thorell L. Nucleotide and polyamine levels in colostrum and mature milk in relation to maternal atopy and atopic development in the children. Acta Paediatr 1999, 88:1338-1343. 10.1111/j.1651-2227.1999.tb01047.x, 10626518.
5. Carver JD, Pimentel B, Cox WI, Barness LA. Dietary nucleotide effects upon immune function in infants. Pediatrics 1991, 88:359-363.
6. Jordan AN, Jurca R, Abraham EH, Salikhova A, Mann JK, Morss GM, Church TS, Lucia A, Earnest CP. Effects of oral ATP supplementation on anaerobic power and muscular strength. Med Sci Sports Exerc 2004, 36:983-990. 10.1249/01.MSS.0000128198.97260.8B, 15179168.
7. Bannwarth B, Allaert FA, Avouac B, Rossignol M, Rozenberg S, Valat JP. A randomized, double-blind, placebo controlled study of oral adenosine triphosphate in subacute low back pain. J Rheumatol 2005, 32:1114-1117.
8. Rossignol M, Allaert FA, Rozenberg S, Valat JP, Avouac B, Peres G, Le Teuff G, Bannwarth B. Measuring the contribution of pharmacological treatment to advice to stay active in patients with subacute low-back pain: a randomised controlled trial. Pharmacoepidemiol Drug Saf 2005, 14:861-867. 10.1002/pds.1114, 15991263.
9. Herda TJ, Ryan ED, Stout JR, Cramer JT. Effects of a supplement designed to increase ATP levels on muscle strength, power output, and endurance. J Int Soc Sports Nutr 2008, 5:3. 10.1186/1550-2783-5-3, 2253504, 18230170.
10. Kichenin K, Decollogne S, Angignard J, Seman M. Cardiovascular and pulmonary response to oral administration of ATP in rabbits. J Appl Physiol 2000, 88:1962-1968. 10.1063/1.1305828, 10846006.
11. Kichenin K, Seman M, Decollogne S, Angignard J. Chronic oral administration of ATP modulates nucleoside transport and purine metabolism in rats. J Pharmacol Exp Ther 2000, 294:126-133.
12. Pastor-Anglada M, Errasti-Murugarren E, Aymerich I, Casado FJ. Concentrative nucleoside transporters (CNTs) in epithelia: from absorption to cell signaling. J Physiol Biochem 2007, 63:97-110. 10.1007/BF03174089, 17722647.
13. Agteresch HJ, Dagnelie PC, Rietveld T, van den Berg JW, Danser AH, Wilson JH. Pharmacokinetics of intravenous ATP in cancer patients. Eur J Clin Pharmacol 2000, 56:49-55. 10.1007/s002280050719, 10853877.
14. Huyghebaert N, Vermeire A, Remon JP. In vitro evaluation of coating polymers for enteric coating and human ileal targeting. Int J Pharm 2005, 298:26-37. 10.1016/j.ijpharm.2005.03.032, 15894443.
15. Coolen EJCM, Arts ICW, Swennen ELR, Bast A, Cohen Stuart MA, Dagnelie PC. Simultaneous determination of adenosine triphosphate and its metabolites in human whole blood by RP-HPLC and UV-detection. J Chromatogr B 2008, 864:43-51.
16. Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Alyonycheva TN, Safier LB, Hajjar KA, Posnett DN, Schoenborn MA, Schooley KA, et al. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest 1997, 99:1351-1360. 10.1172/JCI119294, 507951, 9077545.
17. Trapp GA. Matrix modifiers in graphite furnace atomic absorption analysis of trace lithium in biological fluids. Anal Biochem 1985, 148:127-132. 10.1016/0003-2697(85)90637-2, 4037295.
18. Haskell CM, Wong M, Williams A, Lee LY. Phase I trial of extracellular adenosine 5'-triphosphate in patients with advanced cancer. Med Pediatr Oncol 1996, 27:165-173. 10.1002/(SICI)1096-911X(199609)27:3<165::AID-MPO6>3.0.CO;2-C, 8699994.
19. Agteresch HJ, Rietveld T, Kerkhofs LG, van den Berg JW, Wilson JH, Dagnelie PC. Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: a randomized clinical trial. J Clin Oncol 2002, 20:371-378. 10.1200/JCO.20.2.371, 11786563.
20. Yegutkin GG. Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim Biophys Acta 2008, 1783:673-694. 10.1016/j.bbamcr.2008.01.024, 18302942.
21. Strohmeier GR, Lencer WI, Patapoff TW, Thompson LF, Carlson SL, Moe SJ, Carnes DK, Mrsny RJ, Madara JL. Surface expression, polarization, and functional significance of CD73 in human intestinal epithelia. J Clin Invest 1997, 99:2588-2601. 10.1172/JCI119447, 508104, 9169488.
22. Mohamedali KA, Guicherit OM, Kellems RE, Rudolph FB. The highest levels of purine catabolic enzymes in mice are present in the proximal small intestine. J Biol Chem 1993, 268:23728-23733.
23. Ngo LY, Patil SD, Unadkat JD. Ontogenic and longitudinal activity of Na(+)-nucleoside transporters in the human intestine. Am J Physiol Gastrointest Liver Physiol 2001, 280:G475-G481.
24. Griffith DA, Jarvis SM. Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta 1996, 1286:153-181. 10.1016/S0304-4157(96)00008-1, 8982282.
25. Fox IH. Metabolic basis for disorders of purine nucleotide degradation. Metabolism 1981, 30:616-634. 10.1016/0026-0495(81)90142-6, 6262603.
26. Huyghebaert N, Vermeire A, Rottiers P, Remaut E, Remon JP. Development of an enteric-coated, layered multi-particulate formulation for ileal delivery of viable recombinant Lactococcus lactis. Eur J Pharm Biopharm 2005, 61:134-141. 10.1016/j.ejpb.2005.04.002, 15967652.
27. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994, 331:836-841. 10.1056/NEJM199409293311303, 8078529.
28. Hu LD, Liu Y, Tang X, Zhang Q. Preparation and in vitro/in vivo evaluation of sustained-release metformin hydrochloride pellets. Eur J Pharm Biopharm 2006, 64:185-192. 10.1016/j.ejpb.2006.04.004, 16797948.
29. The United States Pharmacopeia 1999, The United States Pharmacopeial Convention I, Rockville ed.
30. Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small intestine. Gut 1986, 27:886-892. 10.1136/gut.27.8.886, 1433369, 3732895.
31. Holtmann G, Kelly DG, Sternby B, DiMagno EP. Survival of human pancreatic enzymes during small bowel transit: effect of nutrients, bile acids, and enzymes. Am J Physiol 1997, 273:G553-G558.
32. Fallingborg J, Pedersen P, Jacobsen BA. Small intestinal transit time and intraluminal pH in ileocecal resected patients with Crohn's disease. Dig Dis Sci 1998, 43:702-705. 10.1023/A:1018893409596, 9558022.
33. Washington N, Washington C, Wilson CG. Chapter 7: Drug delivery to the large intestine and rectum. Physiological Pharmaceutics 2001, Taylor & Francis, London, Wilson CG, 2.
34. de Roos NM, de Vries JH, Katan MB. Serum lithium as a compliance marker for food and supplement intake. Am J Clin Nutr 2001, 73:75-79.
35. Muller-Oerlinghausen B, Berghofer A, Bauer M. Bipolar disorder. Lancet 2002, 359:241-247. 10.1016/S0140-6736(02)07450-0, 11812578.
36. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001, 38:1101-1106. 10.1161/hy1101.092839, 11711505.
37. Selby JV, Friedman GD, Quesenberry CP. Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol 1990, 131:1017-1027.
38. Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 2006, 37:1503-1507. 10.1161/01.STR.0000221716.55088.d4, 16675740.
39. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004, 51:321-325. 10.1002/art.20405, 15188314.
40. Snaith ML, Scott JT. Uric acid clearance in patients with gout and normal subjects. Ann Rheum Dis 1971, 30:285-289. 10.1136/ard.30.3.285, 1005769, 5090245.
41. Schumacher HR. The pathogenesis of gout. Cleve Clin J Med 2008, 75(Suppl 5):S2-S4.
42. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981, 78:6858-6862. 10.1073/pnas.78.11.6858, 349151, 6947260.
43. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, Mazzali M, Johnson RJ. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002, 40:355-360. 10.1161/01.HYP.0000028589.66335.AA, 12215479.
44. Chen H, Mosley TH, Alonso A, Huang X. Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2009, 169:1064-1069. 10.1093/aje/kwp033, 2727240, 19299404.
45. Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009, 66:1460-1468. 2795011, 19822770.
46. Markowitz CE, Spitsin S, Zimmerman V, Jacobs D, Udupa JK, Hooper DC, Koprowski H. The treatment of multiple sclerosis with inosine. J Altern Complement Med 2009, 15:619-625. 10.1089/acm.2008.0513, 3189001, 19425822.